Recombinant Rotavirus Antigen Expression for Norovirus Vaccine Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of effective anti-norovirus (NoV) drugs or vaccines has been hindered by the lack of adequate cell lines for viral culture and successful animal models for drug and vaccine evaluation, leading to a need for novel compositions and methods to elicit immunity against NoV.
Innovation Solution
The use of polynucleotides encoding rotavirus (RV) NSP3 protein and heterologous polynucleotides, operably linked to promoters like T7 or T3, to create infectious particles that include antigenic peptides or proteins, such as NoV VP1 or SARS-CoV-2 proteins, to elicit an immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccine development methods are used for norovirus, then the process requires adequate cell lines for viral culture and animal models for evaluation, but these resources are lacking and hinder effective vaccine development
Solution Approach 1:
The patent uses a reverse genetics system as an intermediary platform that enables norovirus research without requiring traditional cell lines or animal models. The system employs engineered cell lines expressing norovirus replication factors (NSP3, NSP4, NSP6) that allow viral RNA replication and protein expression in vitro, serving as a mediator between the virus and conventional research methods.
Solution Approach 2:
The patent creates a simplified copy of the norovirus replication system by introducing viral NSP genes into engineered cell lines. This copying approach allows the essential replication functions to be reproduced in a controllable in vitro system, eliminating the need for complex animal models while preserving the ability to study viral immunity.
2Adaptability or versatility
If recombinant rotavirus expressing exogenous protein is used, then immune response against multiple pathogens can be elicited, but the device complexity increases
Solution Approach 1:
The patent creates a universal vaccine platform using recombinant rotavirus that can express multiple different exogenous proteins (norovirus VP1, SARS-CoV-2 spike protein, etc.). The same reverse genetics system and polynucleotide construction approach can be applied to different pathogens by simply changing the inserted gene sequence, providing multi-functional immunity elicitation capability.
Solution Approach 2:
The patent employs a nested structure where exogenous protein-encoding sequences are inserted into the rotavirus genome segment 7 (replacing or augmenting the NSP3 coding sequence). The heterologous protein is nested within the viral genome structure, allowing co-expression with viral proteins from a single integrated polynucleotide construct.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions induce an immune response against NoV and other pathogens, providing a potential vaccine platform for norovirus and other viruses like SARS-CoV-2.
Implementation Method 1
the polynucleotide is operably linked to a promoter. In some embodiments, the promoter is a T7 promoter or a T3 promoter
Implementation Method 2
infectious particles are provided that comprise a polynucleotide comprising: a sequence encoding a rotavirus (RV) NSP3 protein; and a heterologous polynucleotide
Implementation Method 3
These compositions induce an immune response against NoV and other pathogens, providing a potential vaccine platform for norovirus and other viruses like SARS-CoV-2
Data Source
AI summary
Disclosed herein are polynucleotides encoding recombinant rotaviruses (RVs), methods of using the same, and systems for generating the recombinant RVs.